CellBion Co., Ltd. (KOSDAQ:308430)

Market Cap	350.52B
Revenue (ttm)	2.57B
Net Income (ttm)	-7.30B
Shares Out	12.82M
EPS (ttm)	-570.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,174
Average Volume	224,024
Open	28,100
Previous Close	27,900
Day's Range	26,850 - 29,350
52-Week Range	9,930 - 29,600
Beta	n/a
RSI	62.18
Earnings Date	n/a

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308430

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.